ID: ALA5197911

Max Phase: Preclinical

Molecular Formula: C20H32N8O

Molecular Weight: 400.53

Associated Items:

Representations

Canonical SMILES:  COc1ccccc1N1CCN(CCCCCCNc2nc(N)nc(N)n2)CC1

Standard InChI:  InChI=1S/C20H32N8O/c1-29-17-9-5-4-8-16(17)28-14-12-27(13-15-28)11-7-3-2-6-10-23-20-25-18(21)24-19(22)26-20/h4-5,8-9H,2-3,6-7,10-15H2,1H3,(H5,21,22,23,24,25,26)

Standard InChI Key:  LXKSIEBMEPDEFX-UHFFFAOYSA-N

Associated Targets(Human)

Serotonin 1a (5-HT1a) receptor 14969 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serotonin 2a (5-HT2a) receptor 14758 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serotonin 6 (5-HT6) receptor 9749 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serotonin 7 (5-HT7) receptor 5576 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Dopamine D2 receptor 23596 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 400.53Molecular Weight (Monoisotopic): 400.2699AlogP: 1.84#Rotatable Bonds: 10
Polar Surface Area: 118.45Molecular Species: BASEHBA: 9HBD: 3
#RO5 Violations: 0HBA (Lipinski): 9HBD (Lipinski): 5#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 9.42CX LogP: 2.77CX LogD: 0.20
Aromatic Rings: 2Heavy Atoms: 29QED Weighted: 0.51Np Likeness Score: -1.35

References

1. Kułaga D, Drabczyk AK, Satała G, Latacz G, Rózga K, Plażuk D, Jaśkowska J..  (2022)  Design and synthesis of new potent 5-HT7 receptor ligands as a candidate for the treatment of central nervous system diseases.,  227  [PMID:34710746] [10.1016/j.ejmech.2021.113931]

Source